Jonathan R. Whitfield

5.8k total citations · 2 hit papers
34 papers, 4.0k citations indexed

About

Jonathan R. Whitfield is a scholar working on Molecular Biology, Oncology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Jonathan R. Whitfield has authored 34 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Molecular Biology, 10 papers in Oncology and 9 papers in Cellular and Molecular Neuroscience. Recurrent topics in Jonathan R. Whitfield's work include Cell death mechanisms and regulation (9 papers), Neuroscience and Neuropharmacology Research (6 papers) and Protein Degradation and Inhibitors (6 papers). Jonathan R. Whitfield is often cited by papers focused on Cell death mechanisms and regulation (9 papers), Neuroscience and Neuropharmacology Research (6 papers) and Protein Degradation and Inhibitors (6 papers). Jonathan R. Whitfield collaborates with scholars based in United Kingdom, Spain and United States. Jonathan R. Whitfield's co-authors include Jonathan Ham, Laura Soucek, Lee L. Rubin, Carol Babij, Stephen J. Neame, Gérard I. Evan, Lamorna Brown Swigart, Andreas Eilers, Nicole M. Sodir and Curt M. Pfarr and has published in prestigious journals such as Nature, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Jonathan R. Whitfield

34 papers receiving 3.9k citations

Hit Papers

A c-jun dominant negative mutant protects sympathetic neu... 1995 2026 2005 2015 1995 2008 200 400 600

Peers

Jonathan R. Whitfield
Jonathan Ham United Kingdom
Ryoji Yao Japan
Steven A. Reeves United States
Robert S. Freeman United States
Erick J. Morris United States
Sheelagh Frame United Kingdom
Jonathan Ham United Kingdom
Jonathan R. Whitfield
Citations per year, relative to Jonathan R. Whitfield Jonathan R. Whitfield (= 1×) peers Jonathan Ham

Countries citing papers authored by Jonathan R. Whitfield

Since Specialization
Citations

This map shows the geographic impact of Jonathan R. Whitfield's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan R. Whitfield with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan R. Whitfield more than expected).

Fields of papers citing papers by Jonathan R. Whitfield

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan R. Whitfield. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan R. Whitfield. The network helps show where Jonathan R. Whitfield may publish in the future.

Co-authorship network of co-authors of Jonathan R. Whitfield

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan R. Whitfield. A scholar is included among the top collaborators of Jonathan R. Whitfield based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan R. Whitfield. Jonathan R. Whitfield is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Capone, Emily, Alessia Lamolinara, Manuela Iezzi, et al.. (2024). EV20/Omomyc: A novel dual MYC/HER3 targeting immunoconjugate. Journal of Controlled Release. 374. 171–180. 4 indexed citations
2.
Todorović‐Raković, Nataša & Jonathan R. Whitfield. (2024). Therapeutic implications of the interplay between interferons and ER in breast cancer. Cytokine & Growth Factor Reviews. 75. 119–125. 1 indexed citations
3.
Fluck, Mariano F. Zacarías, Daniel Massó-Vallés, Sílvia Casacuberta‐Serra, et al.. (2023). Reducing MYC's transcriptional footprint unveils a good prognostic gene signature in melanoma. Genes & Development. 37(7-8). 303–320. 5 indexed citations
4.
Fluck, Mariano F. Zacarías, Toni Jauset, Sandra Martínez-Martín, et al.. (2021). The Wnt signaling receptor Fzd9 is essential for Myc-driven tumorigenesis in pancreatic islets. Life Science Alliance. 4(5). e201900490–e201900490. 7 indexed citations
5.
Todorović‐Raković, Nataša & Jonathan R. Whitfield. (2021). Between immunomodulation and immunotolerance: The role of IFNγ in SARS-CoV-2 disease. Cytokine. 146. 155637–155637. 31 indexed citations
6.
Whitfield, Jonathan R., Marie-Ève Beaulieu, & Laura Soucek. (2017). Strategies to Inhibit Myc and Their Clinical Applicability. Frontiers in Cell and Developmental Biology. 5. 10–10. 235 indexed citations
7.
Massó-Vallés, Daniel, Toni Jauset, Erika Serrano, et al.. (2015). Ibrutinib Exerts Potent Antifibrotic and Antitumor Activities in Mouse Models of Pancreatic Adenocarcinoma. Cancer Research. 75(8). 1675–1681. 92 indexed citations
8.
Whitfield, Jonathan R., Trevor D. Littlewood, Gérard I. Evan, & Laura Soucek. (2015). The Estrogen Receptor Fusion System in Mouse Models: A Reversible Switch. Cold Spring Harbor Protocols. 2015(3). pdb.top069815–pdb.top069815. 15 indexed citations
9.
Whitfield, Jonathan R., Trevor D. Littlewood, & Laura Soucek. (2015). Tamoxifen Administration to Mice. Cold Spring Harbor Protocols. 2015(3). pdb.prot077966–pdb.prot077966. 34 indexed citations
10.
Annibali, Daniela, Jonathan R. Whitfield, Emilia Favuzzi, et al.. (2014). Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis. Nature Communications. 5(1). 4632–4632. 145 indexed citations
11.
Soucek, Laura, Jonathan R. Whitfield, Carla P. Martins, et al.. (2008). Modelling Myc inhibition as a cancer therapy. Nature. 455(7213). 679–683. 644 indexed citations breakdown →
12.
Dansen, Tobias B., et al.. (2006). Specific Requirement for Bax, Not Bak, in Myc-induced Apoptosis and Tumor Suppression in Vivo. Journal of Biological Chemistry. 281(16). 10890–10895. 52 indexed citations
13.
Whitfield, Jonathan R., Stephen J. Neame, & Jonathan Ham. (2004). Methods for Culturing Primary Sympathetic Neurons and for Determining Neuronal Viability. Humana Press eBooks. 282. 157–168. 10 indexed citations
14.
Neame, Stephen J., Jonathan R. Whitfield, & Jonathan Ham. (2004). Immunocytochemical Techniques for Studying Apoptosis in Primary Sympathetic Neurons. Humana Press eBooks. 282. 169–178. 1 indexed citations
15.
Whitfield, Jonathan R., et al.. (2003). High-throughput methods to detect dimerization of Bcl-2 family proteins. Analytical Biochemistry. 322(2). 170–178. 9 indexed citations
16.
Eilers, Andreas, et al.. (2001). Direct inhibition of c‐Jun N‐terminal kinase in sympathetic neurones preventsc‐junpromoter activation and NGF withdrawal‐induced death. Journal of Neurochemistry. 76(5). 1439–1454. 91 indexed citations
17.
Whitfield, Jonathan R., Stephen J. Neame, Luc Paquet, Ora Bernard, & Jonathan Ham. (2001). Dominant-Negative c-Jun Promotes Neuronal Survival by Reducing BIM Expression and Inhibiting Mitochondrial Cytochrome c Release. Neuron. 29(3). 629–643. 490 indexed citations
18.
Ham, Jonathan, Andreas Eilers, Jonathan R. Whitfield, Stephen J. Neame, & Bina Shah. (2000). c-Jun and the transcriptional control of neuronal apoptosis. Biochemical Pharmacology. 60(8). 1015–1021. 215 indexed citations
19.
Eilers, Andreas, et al.. (1999). c-Jun and Bax: regulators of programmed cell death in developing neurons. Biochemical Society Transactions. 27(6). 790–797. 13 indexed citations
20.
Ham, Jonathan, Carol Babij, Jonathan R. Whitfield, et al.. (1995). A c-jun dominant negative mutant protects sympathetic neurons against programmed cell death. Neuron. 14(5). 927–939. 725 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026